The combinatory targeting of KRAS mutation and TOPK in NSCLC cells could be of great significance for overcoming the drug resistance of 5‐FU, which needs to be further evaluated in clinical practice. This evidence concerns the gene KRAS and non-small cell lung carcinoma.